Application of preparation for regulating and controlling expression quantity of HSP90B1 in preparation of medicine for preventing or treating polycystic ovarian syndrome

A polycystic ovary and expression technology, applied in the field of biomedicine, can solve problems such as unclear pathogenesis and unclear etiology

Pending Publication Date: 2021-09-03
GUANGDONG WOMEN & CHILDREN HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Since Stein and Leventhal first reported polycystic ovary syndrome (PCOS) in 1935, scientists have conducted painstaking research on this

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of preparation for regulating and controlling expression quantity of HSP90B1 in preparation of medicine for preventing or treating polycystic ovarian syndrome
  • Application of preparation for regulating and controlling expression quantity of HSP90B1 in preparation of medicine for preventing or treating polycystic ovarian syndrome
  • Application of preparation for regulating and controlling expression quantity of HSP90B1 in preparation of medicine for preventing or treating polycystic ovarian syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] 1. Materials and methods

[0023] 1. Collection of clinical samples

[0024] The project team adopted the diagnostic criteria recommended by the European Society for Human Reproduction and Embryos and the American Society for Reproductive Medicine (ESHRE / ASRM) in Rotterdam in 2003:

[0025] (1), rare ovulation or anovulation;

[0026] (2), clinical manifestations of hyperandrogen and (or) hyperandrogenemia;

[0027] (3) Ultrasonic manifestations of polycystic ovaries (one or both ovaries have more than 12 follicles with a diameter of 2-9 mm, and (or) ovarian volume > 10 ml);

[0028] (4) 2 of the above 3 items are met, and other kaolin diseases such as congenital adrenal hyperplasia, Cushing's syndrome, and androgen-secreting tumors are excluded.

[0029] Since the diagnosis of PCOS needs to exclude other related hyperandrogen diseases, professional researchers screen PCOS patients according to the Rotterdam expert meeting.

[0030] Case inclusion criteria are as fo...

Embodiment 2

[0081] 1. Materials and methods

[0082] Take 10 paraffin sections of ovarian tissue from PCOS group (experimental group) and non-PCOS group (control group) for immunohistochemical studies; collect follicle fluid from PCOS patients who visited the reproductive center of Guangdong Provincial Maternal and Child Health Hospital, and isolate and culture the primary PCOS ovarian granulosa cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Volumeaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of a preparation for regulating and controlling the expression quantity of HSP90B1 in preparation of a medicine for preventing or treating polycystic ovarian syndrome. Through the development of the research, HSP90B1 participates in PCOS ovarian granular cell proliferation, so that the apoptosis of granular cells in follicles is reduced, the imbalance of proliferation and apoptosis is caused, sinus follicle atresia is reduced, and polycystic change and ovulation disorder in ovaries are caused, HSP90B1 possibly participates in the pathologic mechanism of PCOS generation and development, and HSP90B1 is likely to become a drug target of PCOS (polycaprolactone).

Description

Technical field: [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of a preparation for regulating the expression of HSP90 B1 in the preparation of drugs for preventing or treating polycystic ovary syndrome. Background technique: [0002] Since Stein and Leventhal first reported polycystic ovary syndrome (PCOS) in 1935, scientists have conducted painstaking research on this disease for nearly 70 years, but the etiology is still unclear, and the pathogenesis is still unclear. One of the most complex research hotspots. A large number of clinical and laboratory studies have shown that the syndrome is a syndrome of endocrine and metabolic disorders caused by the involvement of multiple genes and the interaction with the ovarian microenvironment. It is currently believed that the pathological mechanism of PCOS is related to hyperandrogenism and hyperandrogenism. Insulin resistance is closely related. More than 70% of women wit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/713A61P15/08
CPCA61K31/713A61P15/08
Inventor 李荔曾静胡克莫蕙冯潜繆华章李小芳周嘉禾钟明琳叶喜阳
Owner GUANGDONG WOMEN & CHILDREN HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap